0.240
-0.001
(-0.41%)
Jun 19 - Close
NYSEMKT
real-time data -
Disclaimer
Currency in USD
| Range | 0.24 - 0.25 |
| 52 week | 0.20 - 0.47 |
| Open | 0.24 |
| Vol / Avg. | 0.00/665,927.00 |
| Mkt cap | 74.15M |
| P/E | - |
| Div/yield | - |
| EPS | -0.06 |
| Shares | 308.96M |
| Beta | 2.16 |
| Inst. own | 6% |
Events
May 30, 2013
CEL-SCI at Marcum MicroCap Conference
May 20, 2013
CEL-SCI Annual Shareholder Meeting
|
More events from DailyFinance »
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | -15401.67% | -6078.83% |
| Operating margin | -33629.73% | -6772.26% |
| EBITD margin | - | -6545.09% |
| Return on average assets | -48.67% | -89.22% |
| Return on average equity | -99.38% | -219.12% |
| Employees | 43 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 802, 8229 Boone Boulevard
VIENNA, VA 22182
United States - Map
+1-703-5069460 (Phone)
+1-703-5069471 (Fax)
VIENNA, VA 22182
United States - Map
+1-703-5069460 (Phone)
+1-703-5069471 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
CEL-SCI Corporation (CEL-SCI) is engaged in the business of Multikine cancer therapy; New cold fill manufacturing service to the pharmaceutical industry, and ligand epitope antigen presentation System (LEAPS) technology, with two products, hemagglutinin type 1 and neuraminidase type 1 (H1N1) swine flu treatment for H1N1 hospitalized patients and CEL-2000, a rheumatoid arthritis treatment vaccine.
Officers and directors
| Maximilian de Clara | President, Director | |
| Geert R. Kersten Esq. | Chief Executive Officer, Treasurer, Director | |
| Patricia B. Prichep | Senior Vice President - Operations, Corporate Secretary | |
| John Cipriano | Senior Vice President - Regulatory Affairs | |
| Daniel H. Zimmerman Ph.D. | Senior Vice President - Research, Cellular Immunology | |
| Eyal Talor Ph.D. | Chief Scientific Officer | |
| Alexander G. Esterhazy | Independent Director | |
| C. Richard Kinsolving Ph.D. | Independent Director | |
| Peter R. Young Ph.D. | Independent Director |